Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research
For patients suffering with chronic neuropathic pain the need for suitable novel therapies is imperative. Over recent years a contributing factor for the lack of development of new analgesics for neuropathic pain has been the mismatch of primary neuropathic pain assessment endpoints in preclinical v...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.614990/full |
| _version_ | 1818623205828460544 |
|---|---|
| author | Amy S. Fisher Michael T. Lanigan Michael T. Lanigan Neil Upton Lisa A. Lione |
| author_facet | Amy S. Fisher Michael T. Lanigan Michael T. Lanigan Neil Upton Lisa A. Lione |
| author_sort | Amy S. Fisher |
| collection | DOAJ |
| description | For patients suffering with chronic neuropathic pain the need for suitable novel therapies is imperative. Over recent years a contributing factor for the lack of development of new analgesics for neuropathic pain has been the mismatch of primary neuropathic pain assessment endpoints in preclinical vs. clinical trials. Despite continuous forward translation failures across diverse mechanisms, reflexive quantitative sensory testing remains the primary assessment endpoint for neuropathic pain and analgesia in animals. Restricting preclinical evaluation of pain and analgesia to exclusively reflexive outcomes is over simplified and can be argued not clinically relevant due to the continued lack of forward translation and failures in the clinic. The key to developing new analgesic treatments for neuropathic pain therefore lies in the development of clinically relevant endpoints that can translate preclinical animal results to human clinical trials. In this review we discuss this mismatch of primary neuropathic pain assessment endpoints, together with clinical and preclinical evidence that supports how bidirectional research is helping to validate new clinically relevant neuropathic pain assessment endpoints. Ethological behavioral endpoints such as burrowing and facial grimacing and objective measures such as electroencephalography provide improved translatability potential together with currently used quantitative sensory testing endpoints. By tailoring objective and subjective measures of neuropathic pain the translatability of new medicines for patients suffering with neuropathic pain will hopefully be improved. |
| first_indexed | 2024-12-16T18:37:22Z |
| format | Article |
| id | doaj.art-8299723177ac435bac3c212e0fec5019 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-16T18:37:22Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-8299723177ac435bac3c212e0fec50192022-12-21T22:21:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-02-011110.3389/fphar.2020.614990614990Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional ResearchAmy S. Fisher0Michael T. Lanigan1Michael T. Lanigan2Neil Upton3Lisa A. Lione4Transpharmation Ltd., The London Bioscience Innovation Centre, London, United KingdomTranspharmation Ltd., The London Bioscience Innovation Centre, London, United KingdomSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, United KingdomTranspharmation Ltd., The London Bioscience Innovation Centre, London, United KingdomSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, United KingdomFor patients suffering with chronic neuropathic pain the need for suitable novel therapies is imperative. Over recent years a contributing factor for the lack of development of new analgesics for neuropathic pain has been the mismatch of primary neuropathic pain assessment endpoints in preclinical vs. clinical trials. Despite continuous forward translation failures across diverse mechanisms, reflexive quantitative sensory testing remains the primary assessment endpoint for neuropathic pain and analgesia in animals. Restricting preclinical evaluation of pain and analgesia to exclusively reflexive outcomes is over simplified and can be argued not clinically relevant due to the continued lack of forward translation and failures in the clinic. The key to developing new analgesic treatments for neuropathic pain therefore lies in the development of clinically relevant endpoints that can translate preclinical animal results to human clinical trials. In this review we discuss this mismatch of primary neuropathic pain assessment endpoints, together with clinical and preclinical evidence that supports how bidirectional research is helping to validate new clinically relevant neuropathic pain assessment endpoints. Ethological behavioral endpoints such as burrowing and facial grimacing and objective measures such as electroencephalography provide improved translatability potential together with currently used quantitative sensory testing endpoints. By tailoring objective and subjective measures of neuropathic pain the translatability of new medicines for patients suffering with neuropathic pain will hopefully be improved.https://www.frontiersin.org/articles/10.3389/fphar.2020.614990/fullneuropathic painelectroencephalographytranslatabilitypreclinicalclinicalburrowing |
| spellingShingle | Amy S. Fisher Michael T. Lanigan Michael T. Lanigan Neil Upton Lisa A. Lione Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research Frontiers in Pharmacology neuropathic pain electroencephalography translatability preclinical clinical burrowing |
| title | Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research |
| title_full | Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research |
| title_fullStr | Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research |
| title_full_unstemmed | Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research |
| title_short | Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research |
| title_sort | preclinical neuropathic pain assessment the importance of translatability and bidirectional research |
| topic | neuropathic pain electroencephalography translatability preclinical clinical burrowing |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2020.614990/full |
| work_keys_str_mv | AT amysfisher preclinicalneuropathicpainassessmenttheimportanceoftranslatabilityandbidirectionalresearch AT michaeltlanigan preclinicalneuropathicpainassessmenttheimportanceoftranslatabilityandbidirectionalresearch AT michaeltlanigan preclinicalneuropathicpainassessmenttheimportanceoftranslatabilityandbidirectionalresearch AT neilupton preclinicalneuropathicpainassessmenttheimportanceoftranslatabilityandbidirectionalresearch AT lisaalione preclinicalneuropathicpainassessmenttheimportanceoftranslatabilityandbidirectionalresearch |